Format

Send to

Choose Destination
See comment in PubMed Commons below
Therap Adv Gastroenterol. 2008 Sep;1(2):121-42. doi: 10.1177/1756283X08095883.

Barrett's esophagus and the increasing role of endoluminal therapy.

Author information

  • 1Assistant Professor of Medicine, Temple University School of Medicine, Section of Gastroenterology, 3401 North Broad Street, 8PP, Zone "C", Philadelphia, PA 19140, USA. mssmith@alumni.princeton.edu

Abstract

Barrett's esophagus, or the presence of specialized intestinal mucosa in the esophagus that has a malignant potential, has experienced a rapid increase in diagnosis and prevalence over the past few decades. Once thought to progress to adenocarcinoma in an orderly sequence of increasing dysplasia, recent data suggest the process can be more random. In combination with targeted surveillance endoscopy, recent improvements in technology have aided endoluminal therapy in becoming a cost-effective adjunct to medication. When used in combination, in particular, these ablative therapies have become suitable, if not preferable, alternatives to surgery in many patients.

KEYWORDS:

Barrett's esophagus; esophageal cancer; gastro-esophageal reflux disease

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk